LGND

SEC source: 0002001011-25-000093 · edgardoc.xml · nonDerivative · entry 4

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,055

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $180.9350 to $181.4000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000093 · edgardoc.xml · nonDerivative · entry 3

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,147

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $179.4800 to $180.3100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000093 · edgardoc.xml · nonDerivative · entry 2

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,302

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $177.8750 to $178.6400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000093 · edgardoc.xml · nonDerivative · entry 1

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,498

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $176.6800 to $177.6450. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000082 · edgardoc.xml · nonDerivative · entry 3

Aryeh Jason · CIK 0001376960 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,289

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $171.7250 to $172.2400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000082 · edgardoc.xml · nonDerivative · entry 2

Aryeh Jason · CIK 0001376960 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,243

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $170.6850 to $171.6050. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000082 · edgardoc.xml · nonDerivative · entry 1

Aryeh Jason · CIK 0001376960 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,871

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $169.6625 to $170.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000081 · edgardoc.xml · nonDerivative · entry 1

Zimmermann Martine · CIK 0001994049 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,443

F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.

SEC source: 0002001011-25-000068 · edgardoc.xml · nonDerivative · entry 3

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,522

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $163.9900 to $164.5000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000068 · edgardoc.xml · nonDerivative · entry 2

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,607

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $162.3600 to $162.6000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000068 · edgardoc.xml · nonDerivative · entry 1

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,722

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $161.0300 to $162.0200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000061 · edgardoc.xml · nonDerivative · entry 1

Reardon Andrew · CIK 0001950232 · CLO & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,811

F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.

SEC source: 0002001011-25-000059 · edgardoc.xml · nonDerivative · entry 1

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,989

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

SEC source: 0002001011-25-000053 · edgardoc.xml · nonDerivative · entry 1

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,456

F1 · shares: The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.

SEC source: 0002001011-25-000052 · edgardoc.xml · nonDerivative · entry 1

Reardon Andrew · CIK 0001950232 · CLO & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,136

F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0002001011-25-000051 · edgardoc.xml · nonDerivative · entry 1

Espinoza Octavio · CIK 0001905248 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,852

F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0002001011-25-000050 · edgardoc.xml · nonDerivative · entry 1

Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,467

F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0002001011-25-000048 · edgardoc.xml · nonDerivative · entry 1

Reardon Andrew · CIK 0001950232 · CLO & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,903

SEC source: 0002001011-25-000047 · edgardoc.xml · nonDerivative · entry 1

Reardon Andrew · CIK 0001950232 · CLO & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,403

SEC source: 0002001011-25-000046 · edgardoc.xml · derivative · entry 2

Gray Nancy Ryan · CIK 0001714949 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000046 · edgardoc.xml · nonDerivative · entry 1

Gray Nancy Ryan · CIK 0001714949 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,094

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000045 · edgardoc.xml · derivative · entry 4

Aryeh Jason · CIK 0001376960 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000045 · edgardoc.xml · nonDerivative · entry 1

Aryeh Jason · CIK 0001376960 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,289

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000044 · edgardoc.xml · derivative · entry 2

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000044 · edgardoc.xml · nonDerivative · entry 1

LAMATTINA JOHN L · CIK 0001216074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,724

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000043 · edgardoc.xml · derivative · entry 3

Zimmermann Martine · CIK 0001994049 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000043 · edgardoc.xml · nonDerivative · entry 2

Zimmermann Martine · CIK 0001994049 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,558

F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.

SEC source: 0002001011-25-000043 · edgardoc.xml · nonDerivative · entry 1

Zimmermann Martine · CIK 0001994049 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,746

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000042 · edgardoc.xml · derivative · entry 2

Sabba Stephen L · CIK 0001442372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000042 · edgardoc.xml · nonDerivative · entry 1

Sabba Stephen L · CIK 0001442372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,793

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000041 · edgardoc.xml · derivative · entry 2

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000041 · edgardoc.xml · nonDerivative · entry 1

KOZARICH JOHN W · CIK 0001223000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,390

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000040 · edgardoc.xml · derivative · entry 2

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,783

Underlying: Common Stock · 5,783 shares

Expires 2035-06-06

F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000040 · edgardoc.xml · nonDerivative · entry 1

Haas Jason · CIK 0001883821 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,606

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.

SEC source: 0002001011-25-000037 · edgardoc.xml · nonDerivative · entry 2

Reardon Andrew · CIK 0001950232 · CLO & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,903

F2 · balance_after: The total includes 17 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan.

SEC source: 0002001011-25-000029 · edgardoc.xml · nonDerivative · entry 3

Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,234

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $105.1300 to $106.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000029 · edgardoc.xml · nonDerivative · entry 2

Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,711

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $104.1300 to $105.1000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0002001011-25-000029 · edgardoc.xml · nonDerivative · entry 1

Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,404

SEC source: 0002001011-25-000028 · edgardoc.xml · nonDerivative · entry 2

Espinoza Octavio · CIK 0001905248 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,932

F1 · kind: The reporting person's purchase of Ligand Pharmaceuticals Incorporated ("Ligand") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction.

F2 · balance_after: The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP).

SEC source: 0002001011-25-000028 · edgardoc.xml · nonDerivative · entry 1

Espinoza Octavio · CIK 0001905248 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,432

F1 · kind: The reporting person's purchase of Ligand Pharmaceuticals Incorporated ("Ligand") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction.

F2 · balance_after: The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP).

SEC source: 0001104659-25-035352 · tm2512441-1_4seq1.xml · derivative · entry 2

Sabba Stephen L · CIK 0001442372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,406 shares

Expires 2025-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: These securities, as represented in Column 5, were acquired by a grant of 2,754 shares approved by the Board of Directors of the Company at the 2015 Meeting, as previously reported on the Reporting Person's Form 4, dated 28 April 2015. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,406 shares and the exercise price adjusted to $52.30 pursuant to the OmniAb Inc. separation from the Company.

F2 · derivative.exercise_date: These securities, as represented in Column 5, were acquired by a grant of 2,754 shares approved by the Board of Directors of the Company at the 2015 Meeting, as previously reported on the Reporting Person's Form 4, dated 28 April 2015. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,406 shares and the exercise price adjusted to $52.30 pursuant to the OmniAb Inc. separation from the Company.

SEC source: 0001104659-25-035352 · tm2512441-1_4seq1.xml · nonDerivative · entry 1

Sabba Stephen L · CIK 0001442372 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,584

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities, as represented in Column 5, includes the grant of 1,252 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 14, 2024, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 25 June 2024, which was filed to reflect the 2024 Meeting grant.

SEC source: 0002001011-25-000016 · edgardoc.xml · derivative · entry 2

Reardon Andrew · CIK 0001950232 · CLO & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,043

Underlying: Common Stock · 28,043 shares

Expires 2035-03-04

F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.

SEC source: 0002001011-25-000016 · edgardoc.xml · nonDerivative · entry 1

Reardon Andrew · CIK 0001950232 · CLO & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,783

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0002001011-25-000015 · edgardoc.xml · derivative · entry 3

Espinoza Octavio · CIK 0001905248 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,717

Underlying: Common Stock · 32,717 shares

Expires 2035-03-04

F3 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.

SEC source: 0002001011-25-000015 · edgardoc.xml · nonDerivative · entry 2

Espinoza Octavio · CIK 0001905248 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,363

F2 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0002001011-25-000015 · edgardoc.xml · nonDerivative · entry 1

Espinoza Octavio · CIK 0001905248 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,879

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.8900 to $115.1850, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0002001011-25-000014 · edgardoc.xml · derivative · entry 2

Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,476

Underlying: Common Stock · 93,476 shares

Expires 2035-03-04

F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.

SEC source: 0002001011-25-000014 · edgardoc.xml · nonDerivative · entry 1

Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,724

F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

SEC source: 0002001011-25-000013 · edgardoc.xml · nonDerivative · entry 4

Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,342

F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.